DNX Ventures

DNX Ventures is a Tokyo-based firm with a US-Japan cross-border thesis and a long-standing focus on B2B software, and its healthcare exposure fits inside that broader frame. The firm writes $1M-$5M checks at seed and Series A and operates as one of the few credible early-stage venture firms helping enterprise software founders bridge between the US and Japanese markets. Founders pitching DNX for a healthcare deal should expect a conversation grounded in B2B software and cross-border go-to-market rather than in healthcare specialty.

The declared sub-verticals are health IT software and digital health, with an AI focus. In practice that means interest in enterprise healthcare software, AI applications for healthcare operators and life-sciences customers, and digital health businesses that have a credible Japanese or US-Japan commercial thesis. The firm is generally less active in pure therapeutics, in consumer-only wellness, or in companies with no plausible cross-border component. The strongest fits are B2B software companies whose commercial trajectory benefits from access to Japanese enterprise customers, partnerships, or follow-on capital.

Check sizes of $1M-$5M at seed and Series A position the firm as a meaningful syndicate participant or co-lead at the early stages. Geographically the focus is the cross-border axis between the US and Japan, with portfolio density on both sides of the Pacific. The firm has cultivated relationships with Japanese corporates, strategic partners, and follow-on investors that matter when companies are exploring Japanese market entry, partnerships, or financing rounds with Japanese strategic capital. That cross-border network is part of what founders are accepting when they take a check.

The team is built around investors with backgrounds in venture, technology, and cross-border business development between the US and Japan. Diligence tends to be substantive on the B2B software thesis, the cross-border opportunity, and the realistic shape of go-to-market in both markets. Founders should expect detailed conversations about Japanese enterprise customers, regulatory and partnership dynamics, and the operational realities of running a cross-border company.

For founders, the practical read is that DNX is a credible early-stage partner for B2B healthcare software companies with a cross-border US-Japan thesis. It is less useful for therapeutics, for purely US-domestic plays without Japanese ambition, or for founders who do not benefit from the Japanese strategic angle. The engagement style is hands-on on cross-border execution, with real time spent on Japanese business development, partnerships, and follow-on fundraising from Japanese strategic capital. Founders building healthcare AI and IT software with a credible Japanese commercial story and looking for an early-stage partner who can genuinely help on the cross-border path will find DNX one of the more capable options for that specific role.